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Abstract 
BACKGROUND: There is an urgent need for more effective therapies in 
glioblastoma. Data from a previous unrandomized phase II trial (UKT–03) suggested 
that lomustine/temozolomide (CCNU/TMZ) plus radiotherapy may be superior to 
temozolomide (TMZ) chemoradiotherapy in newly diagnosed O6–methylguanine 
DNA–methyltransferase (MGMT) promotor–methylated glioblastoma. The aim of the 
CeTeG/NOA-09 trial was to further investigate CCNU/TMZ in a confirmatory 
randomized phase III trial. 
 
METHODS: The open–label CeTeG/NOA–09 phase III trial randomized (1:1) patients 
with newly diagnosed MGMT promotor–methylated glioblastoma (age 18–70, 
Karnofsky Performance Score 70% and higher) to standard TMZ chemoradiotherapy 
(TMZ therapy 75 mg/m2/d concomitant to radiotherapy 59·4–60 Gy, followed by 6 
courses TMZ 150–200 mg/m2/d days 1–5/28) or to up to six courses of CCNU (100 
mg/m2 day 1) plus TMZ (100 mg/m2 days 2–6/42) in addition to radiotherapy (59·4–
60 Gy). The primary endpoint was overall survival (OS) in the modified intention–to–
treat (mITT) population comprising all randomized patients having started with their 
allocated chemotherapy. The prespecified test for OS differences was a log–rank test 
stratified for center and recursive partitioning analysis group. The trial is registered 
with ClinicalTrials.gov NCT01149109. 
 
FINDINGS: The trial randomized 141 patients; 129 patients (63 TMZ, 66 CCNU/TMZ) 
constituted the mITT population. Overall survival was superior in the CCNU/TMZ arm 
(p=0·0492). Median OS was prolonged from 31.4 months (95% CI 27·7–47·1 
months) with TMZ to 48.1 months (95% CI 32·6 months–not assessable) with 
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CCNU/TMZ. The hazard ratio for death was 0·60 (95% CI 0·35–1·03) in the 
CCNU/TMZ arm as compared to the TMZ arm. A significant OS difference between 
arms was also found in a secondary analysis of the as–randomized population 
(n=141; p=0·0432; HR 0·60, 95% CI 0·35–1·03). Adverse events grade 3 or higher 
were observed in 50.8% of patients with TMZ and 59·1% of patients with 
CCNU/TMZ. 
 
INTERPRETATION: CCNU/TMZ chemotherapy may improve efficacy as compared 
to TMZ standard therapy in patients with newly diagnosed MGMT promotor–
methylated glioblastoma.  
 
FUNDING: German Federal Ministry of Education and Research  
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Research in context 
Evidence before this study 
Prior to the trial, the standard therapy for newly diagnosed glioblastoma patients was 
radiotherapy (59·4–60 Gy) with concomitant daily low–dose (75 mg/m2/d) 
temozolomide chemotherapy, followed by 6 courses of adjuvant temozolomide 
therapy (150–200 mg/m2/d d1–5, 28–day course). The MGMT promotor methylation 
status is a predictor for the benefit from temozolomid therapy: MGMT promotor–
methylated patients have a particularly high survival benefit from TMZ therapy. A 
single–arm phase II trial (UKT–03) applying CCNU/temozolomide combination 
therapy to newly diagnosed glioblastoma patients found a signal of prolonged overall 
survival for patients with MGMT promotor–methylated glioblastoma. Based on this, 
the CeTeG/NOA–09 trial further analyzed the value of the CCNU/temozolomide 
combination chemotherapy in MGMT promotor–methylated glioblastoma patients in a 
randomized phase III setting.  
 
Added value of this study 
The predefined final analysis of the primary endpoint confirmed that combined 
CCNU/temozolomide chemotherapy plus radiotherapy may improve overall survival 
as compared to standard temozolomide chemotherapy plus radiotherapy.  
 
Implications of all the available evidence 
CCNU/temozolomide combination chemotherapy prolonged survival in a selected 
group of MGMT promoter-methylated patients in this small randomized trial. These 
encouraging results require further confirmation; if confirmed, this regimen has the 
potential to become a standard of care option. Ongoing research aims at further 
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investigating the molecular determinants of response to CCNU/temozolomide and the 
cellular changes induced by combined CCNU/temozolomide chemotherapy. 
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Introduction  
 
Chemotherapy for newly diagnosed glioblastoma has not been substantially 
improved since the registration trial for temozolomide (TMZ).1 The addition of tumor-
treating fields to TMZ was associated with moderate survival prolongation.2 
Randomized trials using dose–intensified TMZ regimens3 or combining TMZ with 
other drugs4–7 have all failed to prolong overall survival (OS). Nevertheless, the 
comparably low toxicity of TMZ suggests that more intense alkylating combination 
therapy may be feasible and should be further investigated. 
 
Nitrosourea compounds are well established in glioma therapy.8-12 They are capable 
to penetrate the brain via an intact blood-brain-barrier. The combination of 
nitrosoureas with TMZ is not a mere dose escalation of alkylating therapy but may 
also combine different qualities of DNA damage with the potential for additive or even 
synergistic effects. In contrast to TMZ exerting its therapeutic effect preferably 
through alkylation of guanine, lomustine (CCNU) has effects beyond DNA alkylation: 
It acts as an bifunctional agent introducing interstrand crosslinks13 and leads to 
carbamoylation of amino acids thus interfering with transcriptional, translational and 
posttransscriptional processes.14 In contrast to the alkylating mode of action shared 
by TMZ and nitrosureas, the non-alkyating modes of action may not depend on the 
O6–methylguanine DNA–methyltransferase (MGMT) promotor methylation status 
and the MGMT enzyme activity which counteracts guanine alkylation. It is therefore 
not surprising that combined nitrosourea and TMZ therapy showed enhanced activity 
in high-grade glioma xenograft models.15 Also, a single-arm trial with BCNU and 
unescalated TMZ provided promising results in patients with inoperable 
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gllioblastoma.16 These concepts and experimental results provide a clear rationale to 
evaluate the efficacy of combined CCNU/TMZ therapy in glioblastoma patients. 
 
The single–arm phase II UKT–03 trial17,18 included 31 patients and explored the 
value of a combined CCNU/TMZ chemotherapy in newly diagnosed glioblastoma. In 
line with previous trials using nitrosoureas8,9 which defined the standard in 2002 
when UKT–03 started, chemotherapy started with the first course during RT. WIth 
CCNU/TMZ combination therapy, UKT–03 found a signal for prolonged OS with a 
median of 23 months as opposed to 15–17 months in contemporary historical 
controls. Yet, OS prolongation was exclusively seen in patients with MGMT 
promotor–methylated glioblastoma. Their median OS was 34·5 months comparing 
favorably to 23·4 months in the TMZ registration trial19 while median OS remained at 
12·5 months in MGMT promotor–unmethylated glioblastoma.18 A favorable OS signal 
was also seen in a non–randomized trial applying CCNU/TMZ to pediatric high–grade 
glioma patients.20 The encouraging data of UKT–03 led to the CeTeG/NOA–09 trial 
which tests whether CCNU/TMZ is superior to TMZ standard therapy in a randomized 
phase III setting. CeTeG/NOA–09 implemented exactly the CCNU/TMZ treatment 
regime of the UKT–03 trial (including omission of RT–concomitant daily 
chemotherapy) and was restricted to patients with MGMT promotor–methylated 
glioblastoma on the base of the previous UKT–03 subgroup analyses. 
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Patients and methods 
 
Trial oversight 
CeTeG/NOA–09 is a randomized phase III trial (EudraCT No. 2009–011252–22; 
ClinicalTrials.gov NCT01149109, protocol available at https://neurologie.uni-
bonn.de/sektionen/klinische-neuroonkologie/therapiestudien.htm) approved by Ethic 
Committees of all 17 participating centers. All patients gave written informed consent. 
All trial procedures adhered to the Declaration of Helsinki and the Guidelines for 
Good Clinical Practice. An independent Data Monitoring and Safety Board reviewed 
all safety–relevant information every 6 months.  
 
Sample size calculation  
CeTeG/NOA–09 had to recruit 128 evaluable patients. The sample size calculation 
was performed using the “PS” power and sample size program.21 The sample size 
was based on the assumption that CCNU/TMZ could increase 2–year OS from 
48·9%18 to 70% (UKT–03: 75%).18 Assuming exponentially distributed survival times 
(event/death rates 0·356 and 0·176 per patient year, hazard ratio 0·50), a constant 
recruitment of 64 evaluable patients per treatment group (+ 4 early dropouts per 
group) over two years with a follow–up of at least two years results in a power of 80% 
for the intended two–sided log–rank test (significance level 0·05). The recruitment 
period initially planned for 24 months (04/2011-04/2013) had to be prolonged until 
06/2014 (last-patient-in) since the rate of MGMT promotor-methylated tumors 
(35.8%) was lower than previously reported (45%).19 The follow–up time of initially 
planned 24 months after last–patient–in had to be prolonged to 34 months (04/2017 
closure of the trial as planned), since a treatment arm–blinded analysis of OS 14 
9 
 
months after last–patient–in showed a low overall mean risk for death of 
0·1994/patient year. The prolongation of the follow–up time to 34 months allowed to 
retain the power of 80% despite the lower event rates.  
 
Participants 
Patients were recruited in 17 German University Hospitals based on the following 
inclusion criteria: no prior chemotherapy or radiotherapy (RT), age 18–70 years, 
newly diagnosed glioblastoma or gliosarcoma (resection or biopsy) centrally 
confirmed (TP, for details see Web Appendix), methylated MGMT promotor 
according to central testing (MDXHealth, Herstal, Belgium, for details see below); 
Karnofsky performance score (KPS) ≥70%; stable or decreasing corticosteroids 
within 5 days prior to randomization; adequate hematologic, hepatic, renal and 
coagulation function. Exclusion criteria included prior malignancy treated less than 5 
years ago, prior medical treatment for any cancer, severe other psychological, 
cognitive, familial, sociological or geographical condition potentially interfering with 
compliance with the study protocol, any other antitumor therapy not described in the 
protocol.  
 
Molecular tumor assessment  
Prior to randomization, tumor specimens were analyzed centrally for MGMT promotor 
methylation using real–time methylation–specific PCR21 and tumors were classified 
as MGMT promotor–methylated if the ratio of MGMT to the β–actin reference gene 
(ACTB) was >2 calculated as (methylated MGMT/ACTB) x 1000.19,22,23 Responding 
to changes implemented by the WHO classification of brain tumors 2016,24 all 
available tumor tissue of patients in the trial was retrospectively reclassified. 
Analyses for α–thalassemia/mental–retardation–syndrome–X–linked (ATRX) loss 
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(immunohisto–chemistry, MAb clone CL0537, Sigma, St. Louis, U.S.A.) and isocitrate 
dehydrogenase (IDH) mutation were performed. IDH mutation analysis was started 
with immunohistochemistry (R132H–specific antibody).25 R132H–immunonegative 
tumors of patients <55 years underwent IDH1/2 pyrosequencing and, in IDH mutated 
cases, 1p/19q codeletion analysis by the multiplex ligation–dependent probe 
amplification method (SALSA probe mix P088; MRC Holland, Amsterdam, The 
Netherlands).  
 
Randomization and treatment 
The CeTeG/NOA–09 trial is an open–label trial. Patients were randomized (1:1) 
according to a predefined SAS–generated randomization list (fax response from the 
Study Center Bonn, for details see Web Appendix).  Involved–field RT (59·4–60 Gy in 
30–33 single day fractions) started 22–35 days after surgery. In the standard TMZ 
arm, patients additionally had daily concomitant TMZ (75 mg/m2) followed by 6 
courses of TMZ (150–200 mg/m2/d for 5 days q4w).1 In the experimental CCNU/TMZ 
arm, patients received up to 6 six–week courses of CCNU/TMZ (CCNU 100 mg/m2 
d1, TMZ 100 mg/m2 d2–6). The first course started on the first day of RT, no daily 
concomitant TMZ therapy was applied (Fig. 2). In case the nadir (white blood count 
(WBC) < 1500/µl or thrombocytes < 50000/µl) occurred after day 25, CCNU was 
reduced by one dose level with the dose levels being 100%, 75% and 50% of the 
initial dose. In case of WBC <1500/µl or thrombocytes <50000/µl at the dose level of 
50%, CCNU had to be permanently discontinued. Depending on the nadirs during the 
first 25 days of the previous course, TMZ had to be decreased to the lower dose 
levels of 75 mg/m2 or 50 mg/m2 or increased stepwise to the higher dose levels of 
120 mg/m2, 150 mg/m2 and 200 mg/m2 according to the following schedule: reduction 
by 1 dose level if WBC was <1500/µl or platelets < 50 000/µl; reduction by 2 dose 
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levels if WBC was <1000/µl or platelets < 25 000/µl; increase by 1 dose level if RT 
was completed and WBC was >2500/µl and platelets >100000/µl. In case of WBC 
<1500/µl or thrombocytes <50000/µl at the lowest dose level of 50 mg/m2, TMZ had 
to be permanently discontinued. In case of any non–hematological toxicity CTCAE 
grade 3/4, the substance causing the toxicity had to be withheld in further courses 
and therapy within the trial may continue with the substance not causing the toxicity. 
The choice of postprogression therapy was left to the treating physician and had to 
be documented at all visits. 
 
Assessments  
Patients were followed by neurological examination and KPS at baseline, at the 
beginning of each course and every 12 weeks after completion of chemotherapy. 
Contrast–enhanced magnetic resonance imaging (MRI) was performed every 12 
weeks until death. Determination of progression (PD) was based on RANO criteria26 
with the following modifications:  (1) Up to 12 weeks after completion of RT, PD was 
only considered for new enhancing lesions outside the radiation field (i.e. beyond the 
80% isodose) or unequivocal histological demonstration of viable tumor. (2) 
According to previous experience with late pseudoprogression,27 PD between week 
12 and 24 after completion of RT could only be diagnosed  if confirmed 4 to 6 weeks 
later by another MRI showing further PD. Progressive disease (PD) had to be 
confirmed by central reference neuroradiology blinded to the protocol (HU, EH). 
Adverse events (AE; CTCAE criteria version 4.0) were recorded until at least 30 days 
after the end of study therapy.  
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Primary and secondary endpoint analyses 
All statistical analyses were performed by an experienced statistician who is one of 
the coauthors (RF). The primary endpoint was OS as measured from day of 
randomization to death or last observation. The modified intent–to–treat population 
(mITT) including all randomized patients who received their first dose of study 
chemotherapy (Fig. 1, CONSORT diagram) represented the population on which, 
according to the protocol, the confirmatory analysis had to be performed. Secondary 
analyses were performed on the as–randomized population (i.e. population usually 
named as the ITT population) and the subpopulation of patients with isocitrate 
dehydrogenase (IDH)1/2 wildtype (wt) tumors.The pre-specified confirmatory analysis 
was performed using a log–rank test with stratification by center and recursive 
partitioning analysis (RPA) group.28 RPA III implies age <50 years + KPS 90–100%, 
RPA IV age < 50 years + KPS 70–80% or age > 50 years + at least partial resection 
+ Mini Mental State Examination (MMSE) 27+ points, RPA V  age > 50 years + 
MMSE <27 or age >50 and biopsy only. All centers with less than 3 randomized 
patients per arm were taken together as one center so that the log-rank analysis had 
11 categories for the feature „center“. Prespecified OS analyses in the mITT 
population also included Cox regression analyses yielding estimated hazard ratios 
(HR) with 95% confidence intervals. Survival was plotted according to the Kaplan 
Meier method. In line with the log–rank test stratified for center and RPA class, the 
graphs included only those patients with control counterparts in the respective center 
x RPA class strata thus enabling a balanced analysis and visualization of survival. 
Progression–free survival (PFS) was a secondary endpoint and analyzed using the 
same methods as described above. Secondary endpoints included best response 
rate as determined by modified RANO criteria in patients with incomplete tumor 
resection and documented postoperative residual disease, frequency of delay of the 
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next chemotherapy course by more than 2 weeks, and acute toxicity according to 
CTCAE V4.0. Further exploratory analyses included pseudoprogression rates and 
application of postprogression therapy. Quality of life (QoL) as determined by EORTC 
QLQ C30 and BN20 questionnaires evaluation of neurotoxicity by neurocognitive 
testing using the Mini Mental State Examination and a neurcognitive test battery 
including Trial Making Test A and B, digit span forward and backwards, Controlled 
Word Association Test for semantic word fluency (animals, food) and lexical word 
fluency were additional secondary endpoints.  
 
 
Role of the funding source 
The German Federal Ministry of Education and Research is a non-commercial funder 
and had no role in study design, collection, analysis and interpretation of data, writing 
of the manuscript, and the decision to submit the manuscript for publication. The 
corresponding author (UH) had the final responsibility for all these steps including 
submission of the manuscript. After data bank closure, UH, TT, RF, CC, MG had 
access to all trial data. 
14 
 
Results  
Patients’ characteristics 
Between 04/2011 and 04/2014, 657 patients in 17 study centers gave informed 
consent for the processing of their tumor tissue in the CeTeG trial. In 4 cases, 
obligatory central reference neuropathology did not confirm glioblastoma histology (3 
anaplastic astrocytoma, 1 pilocytic astrocytoma) and these patients were not 
considered for any further steps in the trial such as MGMT analysis or randomization. 
Thus, 653 patients with confirmed glioblastoma entered central MGMT promotor 
methylation analysis (Fig. 1, CONSORT diagram) and 141 patients with MGMT 
promotor–methylated glioblastoma were randomized. The mITT population 
comprised 129 patients (63 TMZ, 66 CCNU/TMZ). Table 1 shows that the trial 
predominantly included patients with a high performance score (KPS 90–100% in 
82%) and a high rate of complete resections (61%). The distribution of sex was 
imbalanced between the arms but not relevant for OS in the mITT cohort (HR 0.99, 
95% 0.63–1.57, p=0.98) and in the treatment arms (data not shown). There was an 
imbalance of RPA class distribution in 3 large centers (40/129 patients): here, all 17 
patients with RPA 3 or 5 were randomized for CCNU/TMZ while the TMZ standard 
arm only comprised RPA4 patients. In accordance with the 2007 WHO classification 
of CNS tumors29 applicable throughout the recruiting and treatment phase, CeTeG 
included 6 patients having a glioblastoma with oligodendroglial component (GBM–O). 
All 6 GBM–O were IDH mutant and 1p/19q codeleted and thus retrospectively 
reclassified as anaplastic oligodendroglioma (Table 1). 
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Treatment 
Fifty-nine of 63 patients in the standard arm (93·7%) and 60 of 66 patients in the 
experimental arm (90·9%) completed radiotherapy as required with a total dose of 
59·4–60 Gy. Sixty percent of patients with TMZ and 39% with CCNU/TMZ had all 6 
chemotherapy courses. The median number of courses was 6 (TMZ) and 5 
(CCNU/TMZ). The maximum dose level of 200 mg/m2 TMZ was achieved in 66·7% 
(TMZ) and 37·9% (CCNU/TMZ) of patients. Dose reductions below 100 mg/m2/d 
occurred only with CCNU/TMZ (TMZ in 12·2%, CCNU in 26% of patients). Further 
details on dose adjustments (Suppl. Table 1) and mean cumulative daily 
chemotherapy doses (Suppl. Table 2) are provided in the Appendix. The median 
length of courses was 28 days (range 26–111 days) with TMZ and 42 days (range 
36–84 days) with CCNU/TMZ. During courses 4 to 6, the percentage of patients with 
courses substantially delayed for 2–6 weeks was higher with CCNU/TMZ (e.g. 40% 
in course 5) than with TMZ (17% course 5; Suppl. Table 4).  
 
 
Overall survival 
In the pre–specified confirmatory analysis (log–rank test stratified for center and RPA 
class), OS was significantly prolonged with CCNU/TMZ as compared to TMZ 
(p=0·0492). A Kaplan–Meier OS graph including all patients of the mITT population 
with control counterparts in the respective center x RPA class strata is shown in Fig. 
3a. Median OS as taken from this graph is prolonged from 31·4 months (95% CI 
27·7–47·1 months) with TMZ to 48·1 months (95% CI 32·6 months–not assessable) 
with CCNU/TMZ. A multivariable Cox regression analysis with center and RPA class 
as covariates in the mITT population yielded a HR of 0·60 (95% CI 0·35–1·03; 
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p=0·0641). A significant OS difference between treatment arms was also found in the 
as–randomized population (=ITT population, n=141; p=0·0432, stratified logrank test, 
fig. 3b), Median OS as taken from fig. 3b is prolonged from 30·4 months (95% CI 
27·0–44·9 months) with TMZ to 46·9 months (95% CI 31·0–not assessable) with 
CCNU/TMZ.  In this population, the HR was 0·60 (95% CI 0·35–1·03). 
 
In post-hoc sensitivity analyses, a univariate Cox regression analysis for OS in the 
mITT population revealed a HR of 0·90 (95% CI 0·58–1·41). Supplementary Fig. 1a 
shows the Kaplan Meier OS graph corresponding to an unstratified OS analysis of 
the mITT population. In this graph, median OS is 31·4 months with TMZ (95% CI 
27·0–44·8 months) and 37·9 months with CCNU/TMZ (95% CI 29·2–51·4 months, 
p=0·6579). Additional exploratory post-hoc OS graphs taking into account the 
imbalance of RPA class distribution in some centers showed a separation of OS 
curves in favour of the CCNU/TMZ arm: a Kaplan Meier graph with inverse 
probability weights and inclusion of all 129 mITT patients into the analysis (Suppl. Fig 
1b), and a Kaplan Meier graph (89 patients) excluding the 3 centers where the 
standard arm contains only RPA4 patients but no RPA3 or RPA5 patients (Suppl. 
Fig. 1c). 
 
In the mITT subpopulation of patients with IDH–wt glioblastoma (n=103) overall 
survival was prolonged (p=0·0374, stratified log-rank test; HR 0·57, 95% CI 0·30–
1·05, post-hoc analysis). Thus, the inclusion of 6 patients with GBM–O, nowadays 
reclassified as anaplastic oligodendroglioma, and 8 patients with IDH–mut 
glioblastoma, had no influence on the primary endpoint OS.  
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Best response and progression–free survival  
Best respone according to RANO criteria was evaluated in the 50 patients of the 
mITT population (23 TMZ; 27 CCNU/TMZ) who were randomized with a less than 
complete resection (table 1). Three patients (13%) had a partial response upon 
standard TMZ; four patients (14·8%) having CCNU/TMZ had at least a partial 
response, three of them (11·1%) a complete response. Progression–free survival in 
the mITT population (p=0·4113, stratified logrank test, fig. 3c) and in the as-
randomized population (=ITT population; p=0·4735, fig. 3c) did not differ between the 
treatment arms. In the mITT population, median PFS was 16·7 months (95% CI 
11·4–24·2 months) with TMZ and 16·7 months (95% CI 12–32 months) with 
CCNU/TMZ. The HR was 0·91 (95% CI 0·57–1·44; mITT population) and 0·99 (95% 
CI 0·68–1·46; as-randomized/ITT population). Pseudoprogression confirmed by 
central reference neuroradiology (according to RANO) or histology (predominance of 
therapy–induced changes) was found in 5 patients (7·9%) with TMZ and 7 (10·6%) 
with CCNU/TMZ. Interestingly, 6 of the 7 patients with pseudoprogression in the 
CCNU/TMZ arm had a re–resection due to suspected progression which yielded a 
histology compatible with pseudoprogression (standard arm: 2/5 pseudoprogressions 
confirmed histologically).  
 
Postprogression therapy 
The median number of further lines of therapy was 2 (range 1–4) with TMZ and 1 
(range 1–4) with CCNU/TMZ (for details, see Suppl. Table 4). While the overall rate 
of re–operations was higher after CCNU/TMZ (22·2% vs. 30·3%), complete 
resections at progression were performed with similar frequency (7·9% TMZ vs. 9% 
CCNU/TMZ) but re–biopsies were exclusively performed after CCNU/TMZ (4.5%). 
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Re–RT was applied with similar frequency (23·8% TMZ; 18·2% CCNU/TMZ). The 
rate of patients receiving any form of systemic antitumor therapy was higher after 
TMZ (60·3% vs. 48·5%; for details see Suppl. Table 4). Bevacizumab was applied 
with similar frequency (27% TMZ, 30·3% CCNU/TMZ).  
 
Toxicity, quality of life and neurocognition 
Table 2 summarizes AEs observed until 30 days after end of study therapy. There 
was no toxic death. The rate of patients with AEs grade 3/4 was higher with 
CCNU/TMZ (all 59·1%, hematotoxicity 36·4%) than with TMZ (all 50·8%, 
hematotoxicity 28·6%). Infectious complications were not increased with CCNU/TMZ. 
Regarding CNS AEs, there was a more frequent reporting of brain edema with 
CCNU/TMZ. The rate of some CNS symptoms such as speech impairment and 
sensory dysfunction were moderately increased in the experimental arm. The rate of 
nausea was increased from 19% with TMZ alone to 30% with CCNU/TMZ without an 
increase of vomiting. Low–grade alopecia was more frequent after CCNU/TMZ (27% 
vs. 16%). There was no excess of other non–hematologic, non–CNS organ toxicity in 
the CCNU/TMZ arm, in particular, there was no additional liver toxicity (Table 2). All 
patients were also evaluated for AEs reported for a minimum of 2 years after 
randomization (Supplementary Table 5), i.e. far beyond the end of study treatment. 
The extended observation period, potentially confounded by further lines of therapy, 
provided data on infrequent (3–6·1% of patients) vascular events in the CCNU/TMZ 
arm: 4 patients with pulmonary embolism occurring at least four months after 
completion of study therapy were noted in the experimental arm only, although the 
rate of deep venous thromboses was not substantially different between the arms. 
Two patients with CNS hemorrhage (1 subdural, 1 epidural hematoma) had this AE 
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during CCNU/TMZ therapy, another patient had a tumor hemorrhage later during 
bevacizumab therapy. Three patients had an ischemic stroke, 1 of them during 
CCNU/TMZ therapy (Table 2), 2 of them substantially later and after having received 
bevacizumab therapy. The longitudinal analysis of QoL and neurocognitive testing 
did not reveal systematic differences between the treatment arms. Detailed results 
will be presented in a separate publication.  
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Discussion 
 
The CeTeG/NOA–09 results provide evidence that CCNU/TMZ therapy may be 
superior to standard TMZ in patients with newly diagnosed MGMT promotor–
methylated glioblastoma. With CCNU/TMZ, OS was prolonged in the context of well 
tolerable toxicity. This may be a first step to improve drug therapy of glioblastoma 
beyond TMZ monotherapy and could be the initiation of separating drug therapy for 
MGMT–methylated from therapy of MGMT–nonmethylated glioblastoma.  
 
As a limitiation, the CeTeG/NOA–09 was a small trial compared with previous phase 
III trials.1-3,5–8 A small number of patients are bearing the effect leading to significant 
survival differences between the treatment groups. This makes made the 
CeTeG/NOA–09 results more susceptible to confounding factors. For this reason, the 
planning of the trial already tried to anticipate potential imbalances of prognostic 
factors and to minimize their influence by using a test stratified for center and RPA 
class. An analysis stratified for RPA class accounts for known strong prognostic 
factors (KPS, age, extent of resection) since they are constitutive for the compound 
parameter RPA class. Nevertheless, the prespecified stratified log–rank test leads to 
small strata so that imbalances may have substantial influence on the results. For 
example, the definition of the stratified log–rank test statistic implies that patients 
from strata without matching patients in the other treatment arm do not contribute to 
the log–rank analysis. This is a very consequent way to enable valid comparisons. 
However, this characteristic of the stratified log–rank test led to the exclusion of some 
patients (n=20) from the analysis. Under these circumstances, the Cox regression 
model as another prespecified analysis of the primary endpoint OS becomes very 
21 
 
important. The multivariable Cox regression model (HR 0·60; 95% CI 0·35–1·03; 
p=0·0641) largely confirmed the finding of the stratified log–rank analysis of an OS–
prolonging effect in the CCNU/TMZ arm. Importantly, the stratified Cox regression 
model did not exclude any patients from the analysis and takes into account the 
problems with the covariates center and RPA class brought in by the small sample 
size. The treatment effect is further supported by exploratory analyses (Suppl. Fig 1b 
with inverse probability weighting; Suppl. Fig. 1c with analysis of the 14 centers 
without a lack of RPA3/RPA5 patients in the standard arm). Overall, the presence of 
an OS–prolonging effect is well supported by the fact that the predefined primary 
analysis was positive and by corroborating statistial analyses. Nevertheless, the 
results favouring CCNU/TMZ have to be taken with caution and conclusions have to 
consider the above mentioned limitations of the stratified analysis and the results of 
the unstratified analysis (Suppl. Fig. 1a).  
 
As a further limitation, there is a discrepancy between prolonged OS and the lack of a 
difference in PFS. This discrepancy  is not based on differences in further lines of 
therapy: re–irradiations and further chemotherapies were more frequent after TMZ; 
complete reresections and antiangiogenic treatments were similarly applied in both 
arms. An increased rate of late and prolonged pseudoprogressions after CCNU/TMZ 
could may have played a major role. Late and prolonged pseudoprogressions which, 
by definition, would have remained undetected by RANO criteria have already been 
described after CCNU/TMZ.27 The observation that most of the pseudoprogressions 
with CCNU/TMZ (6/7 vs. 2/5 with TMZ) were defined only by histology would be in 
line with this hypothesis. One could even hypothesize that undetected 
pseudoprogression was particularly prevalent in the first 2 years after the start of 
therapy thus providing an explanation for the observation that the PFS curves start 
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separating late after 2 years (Fig. 3c). Future studies will have to analyze this 
phenomenon prospectively. Another influencing factor for the lack of a clear PFS 
signal would be the comparably small size of the trial which made the detection of 
small PFS differences less likely. One could speculate whether the observed OS 
prolongation may be in part due to long–term effects of CCNU as already described 
for lower grade tumors.30 Finally, the PFS graph (Fig. 3b) with a late separation of 
curves could also suggest that, regarding PFS, there may be two populations, one 
with and one without an additional benefit brought by combined CCNU/TMZ therapy. 
It will be interesting to see whether there are molecular differences between the 
tumors in these two groups.  
 
Interestingly, median survival in the TMZ standard arm of CeTeG (31·4 months, 95% 
CI 27·7–47·1 months) is prolonged as compared to historical controls of patients with 
a MGMT promotor-methylated tumors (26·4 months, 95% CI 23·9–34·7 months, 
CENTRIC trial6, 21·7 months, 95% CI not supplied, TMZ registration trial19). Also, the 
2 year survival rate was higher in the standard arm of CeTeG/NOA-09 (69%, 95%CI 
58-83%) as compared to the CENTRIC trial (56%, 95% CI 49-62%).6 These modest 
differences between CeTeG/NOA-09 and CENTRIC, another trial for newly 
diagnosed glioblastoma patients with recruitment restricted to patients having a 
MGMT-promotor methylated tumor (same MGMT test and identical cutoff values), 
may not be accounted for by improvements in further line therapies since the portfolio 
of available therapies did not change between CENTRIC and CeTeG except for the 
availability of tumor-treating fields (TTF). TTF, however, had not been applied to any 
patient in the CeTeG trial. However, part of the differences may be explained by the 
particularly high rate of completely resected patients (61%; >95% with any type of 
resection) and patients with high performance score (82% with KPS 90+) in 
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CeTeG/NOA–09. Also, age was restricted to <70 years in CeTeG but not CENTRIC. 
These features indicate that the results of the CeTeG/NOA trial cannot be readily 
extrapolated and generalized to an unselected patient population. Also, it would be 
straightforward to apply the results to patients with an at least partially resected tumor 
and/or with a very high KPS although it has to be kept in mind that the subgroups of 
patients with biopsy only and lower KPS are too small to allow a meaningful 
subgroup analysis. In terms of generalization, it also has to be kept in mind that due 
to limitations of the methylation-specific PCR (MS-PCR)31 many neurooncological 
centers nowadays use pyrosequencing32,33 for the determination of the MGMT 
promotor methylation status. Nevertheless, the quantitative methylation-specific PCR 
(MS-PCR)22 applied here was the method of choice for many large randomized 
glioma trials2,6,7,23,34 and was the only certified method for MGMT promotor 
methylation analysis at the time when CeTeG/NOA-09 started.  
 
As another interesting feature of CeTeG/NOA–09, the OS curves of TMZ and 
CCNU/TMZ separate late, about 2 years after randomization. This has not been 
observed in the TMZ registration trial1 and the EF14 trial (tumor–treating fields)2 but 
is well known from trials with 1p/19q–codeleted anaplastic oligodendroglioma.10,11 
One could speculate whether there are, in fact, two populations, one with additional 
benefit CCNU/TMZ and one without. Further analyses will have to look into 
associated molecular markers.  
 
Toxicity of CCNU/TMZ was well acceptable and only in few domains (e.g. 
hematotoxicity) moderately increased compared with TMZ (Table 2). Classical 
CCNU–associated organ toxicities  such as hepatopathy were not observed. The 
vascular AEs occuring predominantly late and with a long interval after termination of 
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first–line therapy (ischemic stroke, pulmonary embolism, see Supplementary 
Material) have to be noted and future cohorts of CCNU/TMZ–treated patients should 
be systematically and prospectively analyzed for such events. Here, a particular 
interest should be put on the potential relationship with supportive therapy such as 
steroids and further lines of antitumor therapy, especially bevacizumab, both known 
to increase the rate of vascular AEs.   
 
In conclusion, the data of the CeTeG trial demonstrated an OS benefit for 
CCNU/TMZ in the context of moderate toxicity. Therefore, CCNU/TMZ may be a 
promising therapeutic option for patients with MGMT promotor-methylated 
glioblastoma (age <70). The OS–positive CeTeG/NOA–09 trial provides a paradigm 
for molecular subgroup–specific therapy of glioblastoma and further optimization of 
combination chemotherapy for patients with MGMT–methylated glioblastoma.  
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Figures 
 
Fig. 1: CONSORT diagram of the CeTeG trial 
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Fig. 2: The CeTeG trial: schematic overview 
Arm A comprises the standard chemotherapy with temozolomide (TMZ). This 
included daily radiotherapy (RT)–concomitant temozolomide therapy (75 mg/m2/d). 
Four weeks after the end of RT, the first of six adjuvant TMZ courses started (150 
mg/m2/d d1–5 of a 28–day course). According to the standard and if no toxicity 
ensued, TMZ had to be escalated to 200 mg/m2/d in further courses (for further 
details on dose adaptations, see Patients and Methods)  
 
In the experimental arm B, CCNU/TMZ therapy (CCNU 100 mg/m2/d d1 and TMZ 
100 mg/m2/d d2–6) was given in six 42–courses. The first course started on the first 
day of radiotherapy. Therefore, there was no extended daily concomitant 
chemotherapy in the experimental arm. In case no toxicity ensued (for details on 
dose adaptations, see Patients and Methods), TMZ had to be escalated stepwise 
(120 mg/m2/d, 150 mg/m2/d) to a maximum daily dose of 200 mg/m2/d in further 
courses.  
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Fig. 3: Survival in the CeTeG/NOA–09 trial. Kaplan Meier graphs of patients with 
control counterparts in the respective center x RPA class strata. Overall survival in 
(a) the mITT population (n=109; p=0·0492 (stratified logrank test), HR 0·60 (95% CI 
0·35–1·03) and (b) the as-randomized  population (=ITT population; n=125; 
p=0·0432 (stratified logrank test), HR 0·60 (95% CI 0·35–1·03)), progression–free 
survival in (c) the mITT population (n=109; p=0·4113 (stratified logrank test), HR 0·91 
(95% CI 0·57–1·44) and (d) the as -randomized population (=ITT population, n=125; 
p=0·4735 (straified logrank test), HR 0·99 (95% CI 0·68–1·46). 
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Tables 
 
  
Table 1: Patient characteristics in the modified intent-to-treat population. P-values were 
computed using chi-squared tests for independence   
  
 
        
      Total  TMZ CCNU/TMZ       
      (n=129) (n=63) (n=66)       
                  
  Gender, n (%)         p=0·0074     
  Male   77 (59·7) 30 (47·6) 47 (71·2)       
  Female   52 (40·3) 33 (52·4) 19 (28·8)       
                  
  Median age, years (range)     56 (28-70) 59 (31-71) p=0·21     
  <50 years   29 (22·5) 11 (17·5) 18 (27·3)       
  ≥50 years   100 (77·5) 52 (82·5) 48 (72·7)       
                  
  Initial KPS, n (%)         p=0·25     
  90-100%   106 (82·2) 49 (77·8) 57 (86·4)       
  70-80%   23 (17·8) 14 (22·2) 9 (13·6)       
  Not done               
                  
  Extent of resectiona, n (%)         p=0·71     
  Stereotactic biopsy   4 (3·1) 1 (1·6) 3 (4·5)       
  Partial resection   46 (35·7) 22 (34·9) 24 (36·4)       
  Complete resection   79 (61·2) 40 (63·5) 39 (59·1)       
                  
  MMSE, n (%)         p=0·62     
  <27   19 (14·7) 8 (12·7) 11 (16·7)       
  ≥27   108 (83·7) 55 (87·3) 53 (80·3)       
  Missing   2 (1·6) 0 (0) 2 (3·0)       
                  
  Molecular subgroup, n (%)         p=0·32     
  GBM IDHwt   103 (79·8) 52 (82·5) 51 (77·2)       
  GBM IDHmut   8 (6·2) 5 (7·9) 3 (4·6)       
  GBM-O   6 (4·7) 3 (4·8) 3 (4·6)       
  NA   12 (9·3) 3 (4·8) 9 (13·6)       
                  
  RPA groupb, n (%)         p=0·25     
  III   25 (19·4) 9 (14·3) 16 (24·2)       
  IV   88 (68·2) 47 (74·6) 41 (62·1)       
  V   16 (12·4) 7 (11·1) 9 (13·6)       
                  
  aas determined by early (≤72n) post-operative contrast-enhanced MRI; bRecursive partitioning analysis group according      
  to the modified EORTC classification28, *p=0·007, chi-square test,            
  
 
Abbreviations: TMZ temozolomide, CCNU lomustine, KPS Karnofsky performance score, MMSE Mini mental state      
  examination, GBM glioblastoma, IDH isocitrate dehydrogenase, GBM-O glioblastoma with oligodendroglial component,      
  wt wildtype, mut mutated               
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  Table 2: Adverse events in the CeTeG trial until 30 days after end of study treatment (mITT population)       
    TMZ    CCNU/TMZ     
  No. of patients (%) (n=63)   (n=66)     
    All grades     Grade 3/4       Grade 5 All grades Grade 3/4 Grade 5   
  Hematotoxicity      
- 
    
- 
  
  Leukopenia 10 (15·9) 8 (12·7) 24 (36·4)  10 (15·2)   
  Neutropenia 7 (11·1) 4 (6·3) 12 (18·2) 8 (12·1)   
  Thrombocytopenia 19 (30·2) 15 (23·8) 40 (60·6) 19 (28·8)   
  Lymphopenia 4 (6·3) 4 (6·3) 6 (9·1) 3 (4·5)   
  Anemia 3 (4·8) 3 (4·8)   5 (7·6) 1 (1·5)     
  Infections               
  Upper Airways 7 (11·1) -   9 (13·6) -     
  Lung 4 (6·3) 1 (1·6) - 2 (3·0) 2 (3·0) -   
  Gastrointestinal 1 (1·6) -   3 (4·5) 1 (1·5)     
  Wound, other than CNS 1 (1·6) 1 (1·6)   3 (4·5) 3 (4·5)     
  Fatigue 14 (22·2) -   17 (25·8) -     
  Gastrointestinal               
  Nausea 12 (19·0) -   20 (30·3) -     
  Vomiting 8 (12·7) -   6 (9·1) -     
  Diarrhoea 4 (6·3) - - 2 (3·0) - -   
  Constipation 12 (19·0) -   15 (22·7) -     
  Anorexia 2 (3·2) -   4 (6·1) -     
  Weight loss 1 (1·6) -   2 (3·0) -     
  Stomatitis 1 (1·6) -   4 (6·1) -     
  Liver/Pancreas     
- 
    
- 
  
  Elevated transaminases 4 (6·3) - 3 (4·5) -   
  Elevated gammaGT - - 4 (6·1) 4 (6·1)   
  Elevated Bilirubine 1 (1·6) - - -   
  Elevated Lipase 2 (3·2) 1 (1·6) - -   
  Cardial/Vascular               
  Arrhythmia 2 (3·2) -   - -     
  Hemorrhage - - - 2 (3·0) - -   
  Hypertension - -   1 (1·5) -     
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  Venous Thrombosis  2 (3·2) 2 (3·2)   3 (4·5) 1 (1·5)     
  Pulmonary embolism - -   - -     
  Neurological/psychiatrical               
  Seizures 16 (25·4) 4 (6·3)   17 (25·8) 6 (9·1)     
  Ischemic stroke - -   1 (1·5) 1 (1·5)     
  CNS bleeding - -   2 (3·0) -     
  Brain edema 2 (3·2) 1 (1·6)   9 (13·6) 2 (3·0)     
  Memory impairment 1 (1·6) -   2 (3·0) -     
  Motor dysfunction 10 (15·9) 2 (3·2)   8 (12·1) 2 (3·0)     
  Sensory dysfuntion 1 (1·6) -   7 (10·6) 1 (1·5)     
  Speech impairment 4 (6·3) - - 9 (13·6) 3 (4·5) -   
  Cognitive disturbance 2 (3·2) -   5 (7·6) -     
  Personality change 2 (3·2) 1 (1·6)   5 (7·6) -     
  Anxiety - -   3 (4·5) -     
  Sleeping problems 4 (6·3) -   5 (7·6) -     
  Incontinence 1 (1·6) -   - -     
  Hearing impariment 2 (3·2) -   1 (1·5) -     
  Dysgeusia - -   5 (7·6) -     
  Dizziness 6 (9·5) -   5 (7·6) -     
  Wound problems CNS/Skull 3 (4·8) 2 (3·2)   2 (3·0) 1 (1·5)     
  Skin               
  Alopecia 10 (15·9) 1 (1·6)   18 (27·3) 1 (1·5)     
  Erythema 2 (3·2) 1 (1·6) - 6 (9·1) - -   
  Exanthema/Rash 9 (14·3) -   7 (10·6) -     
  Pain               
  Headache 12 (19·0) -   12 (18·1)       
  Radicular/peripheral nerve 2 (3·2) - - 1 (1·5) -     
  Muscle 1 (1·6) -   2 (3·0)       
  Joints 2 (3·2) -   4 (6·1)       
  Abbreviations: No. Number, TMZ temozolomide, CCNU lomustine           
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Supplementary Material: Methods 
 
Trial oversight 
The sponsor of the trial was the University of Bonn. All sponsor-related duties were 
guided by standard operating procedures established at the Clinical Study Core Unit 
(Study Center Bonn) and the Center for Clinical Studies at the University of Cologne 
(ZKS Cologne). In this investigator-initiated trial, the principal investigator (PI, Ulrich 
Herrlinger) had the additional function of the sponsor-delegated person (SDP), which 
is in accordance with the Good Clinical Practice Guideline (ICH-E6; 1.54) and 
European law (regulation 536/2014 article 71). As designee of the sponsor, the 
PI/SDP was responsible for all sponsor-related functions including the proper conduct 
of the trial according to the protocol, correct analysis and interpretation of the 
resulting data, and the communication with regulatory authorities. The study 
coordinator (Martin Glas) supported the PI/SDP in the communication with the 
different trial sites, especially concerning the medical treatment. To be able to 
perform all the sponsor duties in high quality, the PI/SDP was supported by the 
Clinical Study Core Unit (Study Center Bonn, Head Christoph Coch; biometry, project 
management, quality management) and the Center for Clinical Studies at the 
University of Cologne (ZKS Cologne; data management, monitoring,  
pharmacovigilance). All procedures associated with randomization, data acquisition 
and monitoring were carried out so that the PI/SDP could not interfere with these 
processes. The data acquisition and monitoring were performed by the Center for 
Clinical Studies at the University of Cologne and the randomization by the Clinical 
Study Core Unit at the Study Center Bonn. Thus, these essential processes were all 
performed at locations separated from the Bonn trial site at the Division of Clinical 
Neurooncology/Department of Neurology. 
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The randomization list was generated using SAS at the Institute for Medical Biometry, 
Informatics and Epidemiology (IMBIE, Rolf Fimmers). The randomization was 
blocked with a block size of 6 and was stratified for center by allocating complete 
blocks to a center. The randomization list was kept at the Study Center Bonn without 
access for any external individual, including the PI/SDP and the clinical study team of 
the PI at the Division of Clinical Neurooncology. By fax, the trial sites contacted the 
team of Clinical Study Core Unit (Study Center Bonn) for randomization. After 
checking the in- and exclusion criteria listed on the randomization fax form, the trial 
site received a fax with the randomization details incl. the allocation to the treatment 
arm. Every randomization was documented, including the person performing the 
randomization at the Clinical Study Core Unit (Study Center Bonn). The trial site of 
the PI at the Division of Clinical Neurooncology had to undergo exactly the same 
ranodmization procedure for its patients as all other centers in the trial. 
 
The PI and the leading statistician (Rolf Fimmers) had no access to the data of the 
trial until the export of the full data base from the ZKS Cologne to the IMBIE. This 
took place after the closure of trial and closure of the trial data bank, which prior to 
that had undergone final monitoring and quality checks. There were 2 exceptions to 
this rule: (1) Every 6 months until the end of the treatment phase of the last patient 
randomized, the ZKS Cologne provided a safety report with frequencies of serious 
adverse reactions and adverse event rates for the discussion in the independent 
Drug Monitoring and Safety Board meetings. (2) Fourteen months after last-patient-
in, a blinded survival analysis was performed to estimate the overall event rate in the 
whole study population. The leading statistician received survival data blinded for the 
treatment arm and the only information that the PI received was the event rate for 
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death in the whole study population. This data point was only used to determine the 
prolongation of the follow-up time until final closure of the trial. After the delivery of 
the final database, the leading statistician statistician (RF) and the PI (together with 
TT, CC and MG) had full access to all aspects of the data. According to standard 
operating procedures, the primary endpoint analysis was performed by the leading 
statistician (RF) and a second calculation (yielding identical results) was carried out 
by another statistician at the IMBIE. 
 
 
Recruitment of patients, central reference neuropathology and central MGMT 
testing 
The recruitment of patients was a two-step process: In the first step taking place up 
to three weeks after operation/biopsy, patients were screened and informed consent 
was obtained for the central reference neuropathology (TP, Institute for 
Neuropathology, University of Bonn) and MGMT promotor methylation (MDX Health, 
Herstal, Belgium) testing as a study procedure. Paraffin-embedded tumor specimens 
were shipped to central reference neuropathology, and, only after confirmation of 
glioblastoma/gliosarcoma diagnosis, slides with confirmed tumor (position of the 
tumor marked on the slide for extraction) were sent to central MGMT analysis, both 
by overnight carrier. The whole process was documented and guided by standard 
operation procedures. Results of the MGMT promotor methylation analysis were 
directly reported to the centers (turnaround time from sending to neuropathology until 
reception of the MGMT results about 14 days). If then all other inclusion criteria 
applied incl. methylated MGMT promotor status, the informed consent for 
randomization and treatment within the trial was obtained and randomization using a 
fax form including the check of the inclusion/exclusion criteria ensued. 
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Randomization could only be performed if the treatment could start within 35 days 
after operation/biopsy.  
 
 
Kaplan Meier plot with inverse probability weights 
The supplementary results include a Kaplan Meier plot for overall survival applying 
inverse probability weights. This technique up– or down–weights patients treated in a 
center with an RPA class distribution different from the one in the whole study 
population (factor >1 for patients underrepresented, factor <1 for patients 
overrepresented in this center). The calculation of a Kaplan Meier plot with inverse 
probability weights was based on 3 strata for RPA class (RPA class 3, 4, and 5) and 
2 strata for center (1 stratum comprising the 40 patients treated in centers with no 
RPA3 or RPA5 patients in the standard arm and 1 stratum comprising the 89 patients 
treated in centers without this sort of imbalance). For a combination of stratifiers 
(RPA and center) containing in total s = sexp + sc patients  (sexp experimental 
CCNU/TMZ arm, sc control group) these patients obtained weights in the proportions 
s/2 x sexp and s/2 x sc, thus balancing for the over– or underrepresentation of one of 
the treatment groups in each stratum.    
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Supplementary Figure 
 
 
Supplementary Figure 1: Overall survival in the CeTeG trial, post-hoc analyses 
(a) Kaplan–Meier graph for overall survival including all 129 patients of the mITT 
population (unstratified log–rank analysis p=0·6579; univariate Cox regression 
analysis HR 0·90, 95% CI 0·58–1·41). The median overall survival was prolonged 
from 31·4 months with TMZ (95% CI 27·0–44·8 months) to 37·9 months with 
CCNU/TMZ (95% CI 29·2–51·4 months). (b) Kaplan–Meier graph for overall survival 
including data from all 129 patients of the mITT population and using inverse 
probability weights to account for the fact that in 3 centers of the trial all patients with 
RPA class 3 or 5 belonged to the experimental arm and none to the standard arm. 
Based on this graph, median overall survival was prolonged from 30·4 months (95% 
CI 27–44·9 months) in the TMZ arm to 46·9 months (95% CI 31–NA months) in the 
CCNU/TMZ arm. Also, the 4–year OS rate was increased from 31·4% (20·8–47·5%) 
to 48·8% (37·5–63·5%) (c) Kaplan–Meier graph including 89 patients from all centers 
except for the 3 centers with only RPA class 4 (and no class 3 or 5) patients in the 
standard arm (stratified log–rank test p=0·0378; multivariate Cox regression analysis 
with center and RPA class as covariates HR 0·53, 95% CI 0·29–0·99). The median 
overall survival was prolonged from 29·4 months (95% CI 23·9 –34·4 months) in the 
TMZ arm to 46·9 months (95% CI 29.3–54.5 months) 
 
 
 
 
 
 
44 
 
 
a 
b 
c 
45 
 
Supplementary Tables 
 
  Supplementary Table 1: Application of chemotherapy in the CeTeG trial (mITT population)   
        TMZ (n=63)    CCNU/TMZ (n=66)   
  Median number of adjuvant            
  courses (range)           
    6 (0-6) 5 (1-6)   
              
  Number of            
  courses started (N; %)           
  RT-concomitant therapy 63 100 - -   
  course 1 53 84·1 66 100   
  course 2 48 76·2 61 92·4   
  course 3 46 73 53 80·3   
  course 4 45 71·4 48 72·7   
  course 5 40 63·5 36 54·6   
  course 6 38 60·3 26 39·4   
              
  Maximal TMZ dose escalation (N;%)           
  no adjuvant TMZ course 10 15·9       
  100 mg/m2 2 3·2 24 36·4   
  120-125 mg/m2 2 3·2 12 18·1   
  150 mg/m2 7 11·1 5 7·6   
  200 mg/m2 42 66·7 25 37·9   
  Abbreviations: RT radiotherapy, TMZ temozolomide, CCNU lomustine       
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Supplementary Table 2: Cumulative daily doses of chemotherapy applied (mITT 
population) 
  
Cumulative daily doses (mg/m2/day) per patient 
during cycle therapy TMZ CCNU/TMZ   
  TMZ (mg, mean ± stdev) 882+/-334 489 +/- 261   
        25th percentile 750 270   
        50th percentile 1000 470   
        75th percentile 1150 745   
        maximum 1150 870   
  CCNU (mg, mean +/- stdev) - 351 +/- 139   
        25th percentile - 275   
        50th percentile - 400   
        75th percentile - 500   
        maximum - 540   
  Abbreviations: RT radiotherapy, TMZ temozolomide, CCNU lomustine   
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Supplementary Table 3: Summary of further tumor therapy in both arms of the 
CeTeG/NOA-09 trial (mITT population)     
      
TMZ              
(n=63) 
CCNU/TMZ 
(n=66)   
  
Any further line 
therapy   
41 (65·1%) 40  (60·1%) 
  
  
No further therapy 
documented   
22 (34·9%) 26 (39·4%) 
  
    
No progressive disease, alive 11 (17·5%) 12 (18·2%) 
  
    
Progressive disease or death 11 (17·5%) 14 (21·2%)  
  
  
Re-operation 
  
15 (23·8%) 20 (30·3%) 
  
  
Re-radiotherapy 
  
15 (23·8%) 12 (18·2%) 
  
  
Any form of systemic 
antitumor therapy   
39 (61·9%) 33 (50%) 
  
    
TMZ monotherapy 26 (41·3%) 26 (39·4%) 
  
    
CCNU monotherapy or procarbacine/CCNU 10 (15·9%)   3 (4·5%) 
  
    
CCNU/TMZ   3 (4·8%)   1 (1·5%) 
  
    
Carboplatin/Etoposide 0 (0%)   1 (1·5%) 
  
  
       BEV monotherapy or in any combination with BEV  18 (28·6%) 21 (31·8%) 
  
      
BEV +/- irinotecan   9 (14·3%) 17 (25·8%) 
  
      
BEV + any alkylating chemotherapy   9 (14·3%)   4 (6·1%) 
  
    
Nivolumab   1 (1·6%)   1 (1·5%) 
  
    
Experimental multikinase inhibitor   1 (1·6%)   1 (1·5%) 
  
  Abbreviations: TMZ temozolomide, CCNU lomustine, BEV bevacizumab       
 
 
48 
 
 
  
Supplementary Table 4: Frequency of dose delays during the adjuvant chemotherapy courses 
(mITT population)   
  
Start of course Delay 
TMZ arm                          
(% of evaluable 
patients) 
CCNU/TMZ arm              
(% of evaluable 
patients)  
  
  
2 timely or less than 2 weeks delay  92 82·5   
    
delay 2-6 weeks 6·0 14·3 
  
    
delay more than 6 weeks  2·0 3·2 
  
  
3 timely or less than 2 weeks delay  80·9 83·3   
  
 
delay 2-6 weeks 17·0 13·0 
  
  
 
delay more than 6 weeks 2·1 3·7 
  
  
4 timely or less than 2 weeks delay  77·8 75·5   
    
delay 2-6 weeks 6·7 22·4 
  
    
delay more than 6 weeks 0·0 2·0 
  
  
5 timely or less than 2 weeks delay  80·5 55·3   
  
 
delay 2-6 weeks 17·1 39·5 
  
  
 
delay more than 6 weeks 2·4 5·3 
  
  
6 timely or less than 2 weeks delay  76·3 45·2   
    
delay 2-6 weeks 21·1 38·7 
  
    
delay more than 6 weeks 2·6 16·1 
  
  
Abbreviations: RT radiotherapy, TMZ temozolomide, CCNU lomustine 
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  Supplementary Table 5: Adverse events in the CeTeG trial until at least 2 years    
  
 after end of study treatment  
(mITT population)           
  
  TMZ  CCNU/TMZ     
  
  
Number of patients 
(%) (n=63) (n=66)       
    All grades  Grade 3/4     Grade 5 All grades Grade 3/4 Grade 5   
  Cardial/Vascular               
  Arrhythmia 3 (4·8) 1 (1·6)   - -     
  Hemorrhage - - - 2 (1·5) - -   
  Hypertension 3 (4·8) -   2 (3·0) 1 (1·5)     
  Venous thrombosis  3 (4·8) 2 (3·2)   3 (4·8) 1 (1·5)     
  Pulmonary embolism - -   4 (6·1) 3 (4·5)     
  
Neurological/         
psychiatric               
  Seizures 21 (33·3) 9 (14·3)   24 (36·4) 10 (15·2) 1 (1·5)   
  Ischemic stroke - -   3 (4·5) 2 (3·0)     
  CNS bleeding - -   3 (4·5) -     
  Brain edema 4 (6·3) 2 (3·2)   9 (13·6) 2 (3·0)     
  Memory impairment 1 (1·6) -   2 (3·0) -     
  Motor dysfunction 16 (25·4) 6 (9·5)   16 (24·2) 4 (6·1)     
  Sensory dysfuntion 3 (4·8) -   9 (13·6) 1 (1·5)     
  Speech impairment 8 (12·7) 2 (3·2) - 17 (25·8) 8 (12·1) -   
  Cognitive disturbance 5 (7·9) -   8 (12·1) 2 (3·0)     
  Personality change 2 (3·2) 1 (1·6)   6 (9·1) 1 (1·5)     
  Anxiety 1 (1·6) -   3 (4·5) -     
  Sleeping problems 4 (6·3) -   6 (9·1) -     
  Incontinence 2 (3·2) -   1 (1·5) -     
  Hearing impariment 3 (4·8) -   1 (1·5) -     
  Headache 13 (20·6) -   14 (21·2)       
  Abbreviations: RT radiotherapy, TMZ temozolomide, CCNU lomustine       
 
